Pasithea Therapeutics (KTTA) Net Cash Flow (2021 - 2026)

Pasithea Therapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 202.66% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at $45.1 million (up 502.43% YoY), while the FY2025 annual figure was $48.3 million, up 613.71% from the prior year.
• Net Cash Flow came in at -$4.8 million for Q1 2026 at Pasithea Therapeutics, down from $51.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $51.0 million in Q4 2025 to a low of -$7.0 million in Q3 2023.
• A 5-year average of -$63868.5 and a median of -$3.1 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 360.45% in 2022 and surged 2168.64% in 2025, its largest moves.
• Pasithea Therapeutics' Net Cash Flow stood at -$5.5 million in 2022, then soared by 41.39% to -$3.2 million in 2023, then rose by 23.87% to -$2.5 million in 2024, then soared by 2168.64% to $51.0 million in 2025, then slumped by 109.38% to -$4.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$4.8 million, $51.0 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison